A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
A Phase IIIb, Single Arm, Multicenter Study of Atezolizumab in Combination With Bevacizumab to Investigate Safety and Efficacy in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
Sponsor: Hoffmann-La Roche
Terminated
The study was completed as pre-specified in the protocol. Study was terminated only for participants who were in the study even after 24 months of follow-up as specified in the protocol.
Other terminated trials from Hoffmann-La Roche
Other Carcinoma, Hepatocellular trials with similar outcome
Listed as NCT04732286, this PHASE3 trial focuses on Carcinoma, Hepatocellular and remains terminated or withdrawn. Sponsored by Hoffmann-La Roche, it has been updated 27 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
27 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 22 earlier versions
-
Mar 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
-
Jun 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE3
-
Jan 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Almería, Spain , Barcelona, Spain , Bilbao, Spain , Castellon, Spain , Córdoba, Spain , Elche, Spain , Jaén, Spain , Las Palmas de Gran Canaria, Spain , Lugo, Spain and 10 more locations